Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility

Qixin Cao, BSa, Yun Wang, BSb, Xiaohui Song, BSc, Weihua Yang, MDb,∗

Abstract
Retinoblastoma (Rb) is the most common intra-ocular malignancy in children. The association of rs2279744, and rs937283 in MDM2 gene, and p21 rs1801270 polymorphism and RB development have been demonstrated. To provide a comprehensive assessment of and to clarify associations between the 3 SNPs (MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270) and the risk of RB, we performed a meta-analysis of all the eligible case-control studies. We searched English databases include PubMed, Embase, Google Scholar, and Cochrane Library, using an upper date limit of January 1, 2018. The association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and the risk of RB were estimated by calculating a pooled OR and 95% CI under a homozygote comparison, heterozygote comparison, dominant model, and recessive model. The statistical power analysis was performed using G*Power. Our meta-analysis showed a significant association between RB susceptibility and MDM2 rs2279744 recessive model (OR = 1.427, 95%CI: 1.107-1.840, P = .006, I² = 0%). Moreover, a significant link was observed between RB risk and MDM2 rs937283 homozygote comparison (OR = 0.471, 95%CI: 0.259-0.858, P = .014, I² = 0%) and recessive model (OR = 0.587, 95%CI: 0.410-0.840, P = .004, I² = 0%). However, no significant relationship between the p21 rs1801270 polymorphism and RB susceptibility was detected in any of the 4 models (P > .05). In conclusion, we found that significant association between the MDM2 rs2279744 polymorphism and increased RB risk, while MDM2 rs937283 polymorphism was associated with significantly decreased RB risk. However, as to the p21 rs1801270 polymorphism, a statistically significant association was not identified for RB.

Abbreviations: CI = confidence interval, MDM2 = mouse double minute 2 homolog, OR = odds ratios, p21 = cyclin-dependent kinase inhibitor 1, p53 = tumor protein p53, RB = Retinoblastoma.

Keywords: meta-analysis, retinoblastoma, rs1801270, rs2279744, rs937283

1. Introduction
Retinoblastoma (Rb) is the most common intra-ocular malignancy in children and its incidence is approximately 1 case for every 15,000 to 28,000 live births.[1,2] Normally, RB presents at a young age, with about two-thirds of all patients diagnosed before 2 years of age.[3] Clinical presentations of RB include strabismus, leukocoria, red eye, nystagmus, and loss of binocularity depending on the tumor location.[4] The primarily treatment for RB are surgery and chemotherapy. Even if the curative effect and survival rate of children have been raised obviously, RB is still a serious threat to the health of children all over the world.[5] RB may develop rapidly during early childhood, thus it is vital to finding tumors early and preserving vision.[6]

Recently, researchers mainly focused on the identification of RB genetic biomarkers such as gene polymorphisms, microRNA, and lncRNA. Interestingly, some studies have shown that a series of other genes, such as cyclin-dependent kinase inhibitor 1 (p21), tumor protein p53 (p53), mouse double minute 2 homolog (MDM2), and MDM4, may influence the development of RB. p21 rs1801270 polymorphism can produce a C to A transversion and cause a substitution from serine to arginine, affecting the DNA binding zinc finger domain of the protein.[7] Moreover, p21 is the primary protein that is upregulated by activated p53 in response to DNA damage.[8] MDM2 gene is an important negative regulator of the p53 suppressor gene, promoting the degradation of p53 through its E3 ubiquitin ligase activity.[9] The association of 2 single nucleotide polymorphisms (SNPs) (rs2279744 and rs937283) in MDM2 gene and RB development have been demonstrated.[10]

To provide a comprehensive assessment and to clarify associations between the 3 SNPs (MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270) and the risk of RB, we performed a meta-analysis of all the eligible case-control studies.

2. Materials and methods
This systematic review and meta-analysis were conducted following the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines.[11] The secondary research
was conducted in our meta-analysis by reviewing previous publications without linking to any human subjects, thus, ethical approval is not required.

2.1. Literature search strategy and selection criteria
To conduct a literature search, we searched English databases including PubMed, Embase, Google Scholar, and Cochrane Library, using an upper date limit of January 1, 2018 with the following strategy: (Retinoblastoma OR Retinal Neuroblastoma OR Retinal Glioma OR Sporadic Retinoblastoma) AND (rs1801270 OR p21 Ser31Arg) OR (rs2279744 OR MDM2 SNP T309G) OR (rs937283 OR MDM2 SNP G2164A). All the included studies must meet the following criteria: studies involving the association between MDM2 rs2279744, MDM2 rs937283 and p21 rs1801270 polymorphisms and risk of RB; case-control studies based on human; studies published in English; studies with usable and sufficient original data for estimating odds ratios (OR) and their 95% confidence interval (CI). The main exclusion criteria were: duplicate articles; reviews and meta-analysis; not case-control studies; animal studies; not relevant to specific polymorphisms or RB; no sufficient and eligible raw data even after contacting the authors.

2.2. Literature data extraction
The following data were extracted from each included studies independently by 2 investigators: the first author’s name, year of publication, country of origin, ethnicity of study population, source of control, patient number of cases and controls, and the association between the 3 SNPs (MDM2 rs2279744, MDM2 rs937283 and p21 rs1801270) and the risk of RB. The extracted data were compared, and discrepancies were solved by consensus.

2.3. Statistical analysis
The association between MDM2 rs2279744 polymorphism and the risk of RB was estimated by calculating a pooled OR and 95% CI under a homozygote comparison (TT vs GG), heterozygote comparison (TG vs GG), dominant model (TT+TG vs GG+GG) and recessive model (TT vs TG+GG). To determine the link between MDM2 rs937283 polymorphism and the RB risk, homozygote comparison (AA vs GG), heterozygote comparison (AG vs GG), dominant model (AA+AG vs GG) and recessive model (AA vs AG+GG) were also operated. Similarly, homozygote comparison (CC vs AA), heterozygote comparison (CA vs AA), dominant model (CC+CA vs AA) and recessive model (CC vs CA+AA) were also conducted to explore the relationship between P21 rs1801270 polymorphism and the susceptibility to RB. The fixed-effects model or random-effects model was selected depending on whether or not heterogeneity existed among studies. The Cochran Q test (ie, the chi-squared test) was applied to estimate heterogeneity among the included relevant studies. If $I^2 < 50\%$, the fixed effects model was applied. Otherwise, the random-effects model was chosen. Furthermore, a prediction interval was calculated under the random-effects model, because it can provide a predicted range for the true effect size. However, studies less than 3 were not calculated prediction interval. It is worth mentioning that publication bias was only effective when there are at least 10 relevant studies exist. Otherwise, publication bias was underpowered and would have led to unreliable results. We therefore decided to quit publication bias in this meta-analysis due to the limited included studies (only 3 trials). All meta-analyses were conducted on STATA12.0 (Stata Corporation, College Station, TX, USA). In addition, statistical power analysis was performed using G*Power 3.1.9.2 with an α level of 5%.

3. Results
3.1. Included studies and the characteristics
Figure 1 showed the process of acquiring eligible studies. 2587 records were identified from PubMed, Embase, Google Scholar, and Cochrane Library. After title and abstract evaluation, 2311 duplicates were removed and 210 were excluded for not reporting the 3 SNPs (MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270) and the risk of RB. Thus, 66 unique studies left for more detailed evaluation. We found that 37 studies were not original research and 20 studies did not involve humans by reading the full text. We therefore have 9 potential studies for further analyses, however, 4 trials were removed for no usable data. Finally, 5 articles with 1526 patients were included in this meta-analysis.

According to the polymorphisms investigated, the characteristics of the included studies were summarized in Table 1. Four studies involved the MDM2 rs2279744,[10,18-20] 2 studies[18,19] showed a lower risk in RB and the rest of studies[10,20] showed no significant association between MDM2 rs2279744 polymorphisms and RB risk. Two studies estimated MDM2 rs937283[10,19] with 1 trial[10] indicated a higher risk of RB and another trial[19] showed MDM2 rs937283 not link with RB risk. Meanwhile, 2 studies investigated p21 rs1801270 polymorphisms[20,21] susceptibility to RB, 1 study[21] observed higher RB susceptibility and the remaining trial[20] showed no significant association between RB susceptibility and p21 rs1801270 polymorphisms. Among the included studies, 2 from China,[10,20] 2 from Brazil,[19,21] and 1 from Italy.[18] Two studies investigated Han Chinese[10,20] and 1 trial involved Caucasian, Mullato or Black,[19] while the ethnicity of 2 studies was not available.[18,21]

The included trials were all case-control studies, the case group all consist of RB patients, and the control group included unrelated individuals,[18] unrelated healthy adults,[19,21] healthy adults[20] and normal control.[10] All included studies obtained blood sample from each recruited individual for genomic DNA extraction, and were all assessed by polymerase chain reaction (PCR).

3.2. MDM2 rs2279744, MDM2 rs937283 and p21 rs1801270 polymorphisms and susceptibility to RB
We pooled 4 studies[10,18-20] involving MDM2 rs2279744 to evaluate the RB risk associated with MDM2 rs2279744 polymorphisms. The meta-analysis showed a significant statistical association between RB susceptibility and MDM2 rs2279744 recessive model (TT vs TG+GG) (OR (95%CI) = 1.427 (1.107–1.840), P = .006, Figure 2D, 95% prediction interval: 0.82–2.50) with the fixed-effects model ($P=0.409$, $I^2=0\%$), while no statistical significance was detected in the 3 genotypes of homozygote comparison (TT vs GG) (OR (95%CI) = 1.307 (0.929–1.841), $P= .125$, Figure 2A, 95% prediction interval: 0.40–4.45) with the fixed-effects model ($P=0.276$, $I^2=22.5\%$), heterozygote comparison (TG vs GG) (OR (95%CI) = 0.935 (0.691–1.265), $P= .664$, Figure 2B, 95% prediction interval: 0.48–1.82) with the fixed-effects model ($P=0.679$, $I^2=0\%$), and
dominant model (TT+TG vs GG) (OR (95%CI) = 1.042 (0.786–1.382), P = .774, Figure 2C, 95% prediction interval: 0.55–1.96) with the fixed-effects model (P = .388, I² = 0.7%). The results indicated that the MDM2 rs2279744 polymorphisms were significantly associated with susceptibility to RB.

Two trials [10,19] were pooled to estimate the association between RB risk and MDM2 rs937283 polymorphisms, a significant statistical association was observed between lower RB risk and MDM2 rs937283 homozygote comparison (AA vs GG) (OR (95%CI) = 0.471 (0.259–0.858), P = .014, Fig. 3A) with the fixed-effects model (P = .581, I² = 0%) and recessive model (AA vs AG+GG) (OR (95%CI) = 0.587 (0.410–0.840), P = .004, Fig. 2D) with the fixed-effects model (P = .334, I² = 0%). However, no significant statistical link was found in the 2 genotypes of heterozygote comparison (AG vs GG) (OR (95%CI) = 0.741 (0.406–1.354), P = .330, Fig. 3B) with the fixed-effects model (P = .964, I² = 0%) and dominant model (AA+AG vs GG) (OR (95%CI) = 0.581 (0.329–1.025), P = .061, Fig. 3C) with the fixed-effects model (P = .708, I² = 0%). The meta-analysis showed a statistical significance between lower RB risk and MDM2 rs937283 polymorphisms.

To investigate the relationship between p21 rs1801270 polymorphisms and susceptibility to RB, we combined 2 trials [20,21] based on homozygote comparison (CC vs AA), heterozygote comparison (CA vs AA), dominant model (CC+CA vs AA) and recessive model (CC vs CA+AA), the pooled ORs (95%CIs) were (1.242 (0.716–2.156), P = .441, Fig. 4A) with the fixed-effects model (P = .437, I² = 0%), (1.077 (0.651–1.781), P = .774, Fig. 4B) with the fixed-effects model (P = .699, I² = 0%), (1.115 (0.694–1.792), P = .654, Fig. 4C) with the fixed-effects model (P = .745, I² = 0%) and (0.824 (0.323–2.103), P = .685, Fig. 4D) with the random-effects model (P = .008, I² = 85.7%), respectively. No significant statistical relationship between the p21 rs1801270 polymorphism in RB susceptibility was detected in any of the 4 models, which indicated that p21 rs1801270 polymorphism was not link with the risk of RB. All results of the analysis were shown in Table 2.

3.3. Power analysis

We calculated the statistical power analysis to reassess the available data when an alpha of 0.05 was assigned. As shown in
Table 2, the statistical power ranged from 9.3% to 54.0% for MDM2 rs2279744 analysis. For MDM2 rs937283 analysis, the statistical power ranged from 14.4% to 78.2%. The power of p21 rs1801270 analysis ranged from 4.5% to 15.5%.

4. Discussion
Early in 1809, RB was first described by the Scottish surgeon James Wardrop, as white brain-like intraocular tumors of retinal origin. With social and economic development, the under-
standing of the mechanism of RB is deeper day by day. Importantly, the gene plays an important role in the development of RB. Almost half of the children with RB have a hereditary genetic defect associated with RB.[23] Although several genetic studies have reported the correlation between MDM2 rs2279744 polymorphism, MDM2 rs937283 polymorphism, or p21 rs1801270 variant and the risk of RB, these results were inconclusive since they are performed in an individual medical center with small sample size and in different ethnicities. Therefore, it is important to perform a meta-analysis of all eligible studies to clarify the effects of MDM2 rs2279744 polymorphism, MDM2 rs937283 polymorphism, or P21 rs1801270 variant on risk of RB.

To the best of our knowledge, the meta-analysis in this study is the largest to study the associations between MDM2 rs2279744, MDM2 rs937283, or P21 rs1801270 polymorphisms and RB risk. In our meta-analysis, based on the database of publications in respect of the MDM2 rs2279744 polymorphism, MDM2 rs937283 polymorphism, and the P21 rs1801270 polymorphism, among which there are 4 studies including 520 cases and 745 controls for MDM2 rs2279744 polymorphism, 2 studies including 241 cases and 254 controls for MDM2 rs937283 polymorphism, and 2 studies including 309 cases and 305 controls for P21 rs1801270 polymorphism respectively. An increased risk of RB was found for the MDM2 rs2279744 polymorphism. Likewise, we observed MDM2 rs937283 polymorphism was significantly associated with a decreased RB risk. Interestingly, as to the P21 rs1801270 polymorphism, a statistically significant association was not identified for RB.

MDM2 rs2279744 (also known as MDM2 SNP T309G) is a G/T single-nucleotide variation on human chromosome 12. It can influence the binding of the transcription factor, Sp1. Sp1 binds with higher affinity to the G allele than to the T allele, which accounts for increased transcription of the MDM2 gene and higher expression levels of MDM2 protein, and thereby inhibits the function of p53 pathway in the prevention of tumor formation.[24] Our results evaluated MDM2 rs2279744 polymorphism may be a risk factor for the development of RB. Prediction intervals were calculated for MDM2 rs2279744. The results of prediction intervals are wide, suggesting that future research may demonstrate benefit, disadvantage, or not demonstrate any statistically significant difference.[25] Similar to our analysis, some meta-analysis demonstrated that MDM2 rs2279744 is associated with squamous cell carcinoma,[26] colorectal cancer,[27] endometrial cancer,[28] and hepatocellular carcinoma.[29] But 2 meta-analyses indicated that MDM2 rs2279744 polymorphism cannot be considered as genetic risk factors for osteosarcoma,[30] and prostate cancer.[27] More interestingly, Xie et al.[31] found MDM2 rs2279744 polymorphism has no influence on bladder cancer risk in Asians, but this single nucleotide polymorphism may be associated with genetic susceptibility of bladder cancer among Caucasians. Considering the above results, we think that MDM2 rs2279744 polymorphism may have tumor suppressor functions under certain conditions. Thus, gene-environment and gene-gene interactions regulate carcinogenesis, and the presence of some other causal factors until now unrealized evaluate an association between MDM2 rs2279744 polymorphism and RB development.
Figure 4. (A) The forest plot of p21 rs1801270 homozygote comparison (CC vs AA) and RB risk; (B) The forest plot of p21 rs1801270 heterozygote comparison (CA vs AA) and RB risk; (C) The forest plot of p21 rs1801270 dominant model (CC+CA vs AA) and RB risk; (D) The forest plot of p21 rs1801270 recessive model (CC vs CA+AA) and RB risk. Rb = Retinoblastoma.

Table 2
Results of Analysis.

|                  | Homozygote Comparison | Heterozygote Comparison | Dominant Model | Recessive Model |
|------------------|-----------------------|-------------------------|---------------|----------------|
|                  | TT vs GG              | TG vs GG                | (TT+TG) vs GG | TT vs (TG+GG)  |
|                  |                       |                         |               |                |
| MDM2-rs2279744   |                       |                         |               |                |
| Heterogeneity    | I² (%)                | 22.5                    | 0             | 0              |
|                  | P                     | .276                    | .679          | .388           |
| Meta-Analysis    | OR (95%CI)            | 1.307 (0.929–1.841)     | 0.935 (0.691–1.265) | 1.042 (0.786–1.382) | 1.427 (1.107–1.840) |
|                  | P                     | .125                    | .664          | .774           | .006           |
|                  | prediction interval   | 0.40–4.45               | 0.48–1.82     | 0.55–1.96      | 0.62–2.50     |
|                  | Power                 | 9.3%                    | 33.6%         | 10.8%          | 54.0%         |
|                  |                       |                         |               |                |
| MDM2-rs937283    |                       |                         |               |                |
| Heterogeneity    | I² (%)                | 0                       | 0             | 0              |
|                  | P                     | .381                    | .364          | .708           | .334           |
| Meta-Analysis    | OR (95%CI)            | 0.471 (0.259–0.858)     | 0.741 (0.406–1.354) | 0.581 (0.329–1.025) | 0.587 (0.410–0.840) |
|                  | P                     | 0.014                   | 0.33          | 0.061          | 0.004          |
|                  | prediction interval   | 0.40–4.45               | 0.48–1.82     | 0.55–1.96      | 0.62–2.50     |
|                  | Power                 | 70.3%                   | 14.4%         | 41.2%          | 78.2%          |
| P21-rs1801270    |                       |                         |               |                |
| Heterogeneity    | I² (%)                | 0                       | 0             | 0              |
|                  | P                     | .437                    | .499          | .746           | .008           |
| Meta-Analysis    | OR (95%CI)            | 1.242 (0.716–2.156)     | 1.077 (0.651–1.781) | 1.115 (0.694–1.792) | 0.824 (0.523–2.103) |
|                  | P                     | 0.441                   | 0.774         | 0.654          | 0.685          |
|                  | prediction interval   | 0.40–4.45               | 0.48–1.82     | 0.55–1.96      | 0.62–2.50     |
|                  | Power                 | 9.1%                    | 15.5%         | 12.8%          | 4.5%           |

CI = confidence interval, OR = odds ratio; a, the association between the 3 SNPs (MDM2-rs2279744, MDM2-rs937283 and p21-rs1801270) and the risk of RB.
MDM2 rs937283 (also known as SNP G2164A) polymorphism could lead to an A to G base change at the 2164 nucleotide in the promoter region of MDM2 gene. Jiao et al. suggested that the MDM2 rs937283 polymorphism is a novel functional SNP both in vitro and in vivo as a biomarker for poor prognosis in RB. However, our meta-analysis proved that MDM2 rs937283 polymorphism was significantly associated with a decreased RB risk. A possible explanation is that our meta-analysis included more studies that have more patients.

The p21 rs1801270A (also named p21 Ser31Arg), which occurs in codon 31, results in an amino acid substitution of arginine for serine. This polymorphism is located in a highly conserved region of p21 and is expected to affect its molecular function. Prior studies have shown an association between the p21 rs1801270A allele and a decreased risk for cervical cancer in a population of Chinese women. However, Taghavi et al. suggested that p21 rs1801270A is not the risk of RB development. A possible reason for this may be that the mechanism of carcinogenesis may differ between different cancer sites and the p21 rs1801270A genetic variants may exert multiple effects in different cancers.

Notably, our analysis is not without limitations. First, only 5 studies were included for the meta-analysis, the case number in each study included in our analysis is relatively small. Moreover, the statistical power for each analysis is not high. Second, gene–gene, gene–environment (including age, environmental factors, lifestyle, and some other factors) and within–gene interactions may modulate RB risk, and therefore should be identified in the future study. Finally, since the included studies were only written in English, the language bias is inevitable.

In conclusion, our meta-analysis found that significant association between the MDM2 rs2279744 polymorphism and increased RB risk. Moreover, MDM2 rs937283 polymorphism was associated with significantly decreased RB risk. Interestingly, as to the P21 rs1801270A polymorphism, a statistically significant association was not identified for RB. Considering the above-mentioned limitations, more adequately powered and well-designed studies are required to verify this conclusion.

Author contributions

Conceptualization: Weihua Yang.
Data curation: Qixin Cao, Yun Wang, and Xiaohui Song.
Methodology: Qixin Cao and Xiaohui Song.
Software: Qixin Cao and Xiaohui Song.
Writing – original draft: Qixin Cao, Yun Wang, and Weihua Yang.
Writing – review and editing: Weihua Yang.

References

[1] Parkin DM, Stiller CA, Draper GJ, et al. The international incidence of childhood cancer. Int J Cancer 1998;42:511–20.
[2] Gallie BL, Campbell C, Devlin H, et al. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999;59:1731s–5a.
[3] Said AMA, Elhoyami AM, Shaat AAK. Structural changes of the macula and optic nerve head in the remaining eyes after enucleation for retinoblastoma: an optical coherence tomography study. BMC Ophthalmol 2017;17:251.
[4] Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics 2003;112:1248–55.
[5] Benavente CA, Dyer MA. Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol 2015;10:547–62.
[6] Skaleta AH, Cominos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology 2018;125:453–8.
[7] Sun Y, Hildebrand A, Li H, et al. No point mutation but a codon 31ser >arg polymorphism of the WAF1/ICIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 1995;4:261–7.
[8] Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980–5.
[9] Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591–602.
[10] Jiao Y, Jiang Z, Wu Y, et al. A functional polymorphism (rs917283) in the MDM2 promoter region is associated with poor prognosis of retinoblastoma in Chinese Han population. Sci Rep 2016;6:31240.
[11] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000;283:2008–12.
[12] Lan A, Xiao F, Wang Y, et al. Efficacy of fibrin glue versus sutures for attaching conjunctival autografts in pterygium surgery: a systematic review with meta-analysis and trial sequential analysis of evidence. Oncotarget 2017;8:41487–97.
[13] Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685–99.
[14] Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J Roy Stat Soc Ser A (Stat Soc) 2009;172:137–59.
[15] Harris R, Bradburn M, Deeks J, et al. Metan: fixed-and random-effects meta-analysis. Stata J 2008;8:3.
[16] Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119–29.
[17] Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using GPower 3.1: tests for correlation and regression analyses. Behav Res Methods 2009;41:1149–60.
[18] Epistologato MC, Duscielo V, Livide G, et al. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma. J Hum Genet 2011;56:685–6.
[19] de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, et al. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr Blood Cancer 2012;59:39:43.
[20] Chen R, Liu S, Ye H, et al. Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population. Sci Rep 2015;5:13300.
[21] Carvalho IN, Reis AH, Cabello PH, et al. Polymorphisms of CDKN1A gene and risk of retinoblastoma. Carcinogenesis 2013;34:2774–7.
[22] Kidola T. 200 years of success initiated by James Wardrop’s 1809 monograph on retinoblastoma. Acta Ophthalmol 2009;87:810–2.
[23] MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma in Great Britain 1963–2002. Br J Ophthalmol 2009;93:33–37.
[24] Tas A, Atabey M, Caglayan G, et al. Investigation of the association between the MDM2 T309G polymorphism and gastric cancer. Biomed Res 2017;7:469–73.
[25] Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. Bmj 2011;342:d549.
[26] Yu H, Li H, Zhang J, et al. Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis. Onco Targets Ther 2016;9:6211–24.
[27] Wang W, Du M, Gu D, et al. MDM2 SNP309 polymorphism is associated with colorectal cancer risk. Sci Rep 2014;4:4851.
[28] Wang LH, Wang X, Xu WT, et al. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol 2014;35:3167–70.
[29] Ma Y, Jian B, Cao H. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One 2013;8:e56918.
[30] Bulbulo-Aldarturriaga N, Akgun Z, Granado-Tajada I, et al. A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility. Pediatr Res 2016;80:472–9.
[31] Xie L, Sun Y, Chen T, et al. Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer; new data in a Chinese population and an updated meta-analysis. Onco Targets Ther 2015;8:3679–90.
[32] Chedid M, Michieli P, Lengel C, et al. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 1994;9:3021–4.
[33] Wang N, Wang S, Zhang Q, et al. Association of p21 SNPs and risk of cervical cancer among Chinese women. BMC Cancer 2012;12:589.
[34] Taghavi N, Bramajamal F, Abbaszadegan MR, et al. P21(waf1/cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: a preliminary study. Arch Iran Med 2010;13:235–42.
[35] Xiao F, Pu J, Wen Q, et al. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer. Oncotarget 2017;8:48488–506.